Pubblicazioni

Autori:

Franzina, Carlotta; Bevere, Michele; Bersani, Samantha; Mattiolo, Paola; Ceccon, Carlotta; Piccoli, Paola; Malleo, Giuseppe; Lawlor, Rita T; Salvia, Roberto; Milella, Michele; Fassan, Matteo; Scarpa, Aldo; Luchini, Claudio

Titolo:

High fidelity of Claudin-18.2 expression in primary and matched metastatic (lymph nodes, peritoneum, and liver) pancreatic ductal adenocarcinoma: a foundation for targeted therapy

Anno:

2026

Tipologia prodotto:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Lingua:

Inglese

Formato:

Elettronico

Referee:

No

Nome rivista:

Human Pathology

ISSN Rivista:

0046-8177

N° Volume:

168

Intervallo pagine:

1-7

Parole chiave:

CLDN18; CLDN18.2; Claudin; Metastases; Metastasis; PDAC; Pancreatic cancer

Breve descrizione dei contenuti:

: Claudin-18.2 (CLDN18.2) is a tight-junction protein that can be expressed in various neoplasms, including pancreatic ductal adenocarcinoma (PDAC). Anti-CLDN18.2 targeted therapies have already been approved for CLDN18.2-positive gastric cancer and are currently being tested in clinical trials for PDAC. This study aims to define the expression patterns and concordance rate of CLDN18.2 in primary and matched metastatic PDAC. Whole-slide immunohistochemistry for CLDN18 was performed on primary PDAC and matched metastases, and was assessed by cell percentage (range: 0-100%) and intensity of CLDN18-positivity (scores 0, 1+, 2+, and 3+), and also using the H-score. Tumor positivity for CLDN18 was determined if ≥75% of tumor cells exhibited 2+/3+ staining. The study's cohort was composed of 20 patients with PDAC and concomitant lymph node metastases (LNM), 30 patients with PDAC and matched peritoneal metastases (PM), and 12 patients with PDAC and concomitant liver metastases (LIVM). The mean value of the percentages of 2+/3+ cells for primary tumors was 46.5%, for LNM was 60%, for PM was 31%, and for LIVM was 22%. The mean value of the H-score for primary tumors was 123.9, for LNM was 183, for PM was 89.1, and for LIVM was 54.6. The correspondence rate between primary PDAC and the matched metastatic sites was: 70.0% for PDAC/LNM, 93.3% for PDAC/PM, and 100.0% for PDAC/LIVM. This study shows a high rate of correspondence of CLDN18-positivity between primary PDAC and different metastatic sites, providing a strong rationale for further exploring and testing anti-CLDN18.2 therapeutic strategies in this lethal malignancy.

Note:

Available online 11 December 2025

Id prodotto:

148801

Handle IRIS:

11562/1177552

ultima modifica:

18 febbraio 2026

Citazione bibliografica:

Franzina, Carlotta; Bevere, Michele; Bersani, Samantha; Mattiolo, Paola; Ceccon, Carlotta; Piccoli, Paola; Malleo, Giuseppe; Lawlor, Rita T; Salvia, Roberto; Milella, Michele; Fassan, Matteo; Scarpa, Aldo; Luchini, Claudio, High fidelity of Claudin-18.2 expression in primary and matched metastatic (lymph nodes, peritoneum, and liver) pancreatic ductal adenocarcinoma: a foundation for targeted therapy «Human Pathology» , vol. 168 , 2026 , pp. 1-7

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo